In the latest trading session,, 0.46 million Matinas Biopharma Holdings Inc (AMEX:MTNB) shares changed hands as the company’s beta touched 1.30. With the company’s most recent per share price at $1.00 changing hands around $0.12 or 13.62% at last look, the market valuation stands at $5.09M. MTNB’s current price is a discount, trading about -860.0% off its 52-week high of $9.60. The share price had its 52-week low at $0.47, which suggests the last value was 53.0% up since then.

Matinas Biopharma Holdings Inc (AMEX:MTNB) trade information

Instantly MTNB is in green as seen in intraday trades today. With action 20.47%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 96.08%, with the 5-day performance at 20.47% in the green. However, in the 30-day time frame, Matinas Biopharma Holdings Inc (AMEX:MTNB) is 58.43% up.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.58%.

MTNB Dividends

Matinas Biopharma Holdings Inc is expected to release its next quarterly earnings report in July.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.2869% or 9.32 million shares worth $1.48 million as of 2024-06-30.

Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . With 58.39 shares estimated at $57219.0 under it, the former controlled 1.15% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held about 0.59% of the shares, roughly 30.0 shares worth around $29399.0.